Jacksonville, Fl — As Hurricane Milton approached in 2024, Michael Klein went to an ophthalmologist because he was seeing a ...
Hemodialysis significantly alters anterior and posterior eye segments, affecting parameters like anterior chamber depth, lens ...
Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious ...
Pharmaceutical Technology on MSN
Samsung Bioepis initiates Byooviz commercialisation in Europe
Samsung Bioepis has started direct commercialisation of Byooviz, a biosimilar to Genentech’s Lucentis (ranibizumab), in ...
Samsung Bioepis has begun direct commercialization of Byooviz in Europe. Byooviz is a biosimilar to Lucentis’ (ranibizumab).
Discover how cardiovascular risk scores can indicate future eye disease risk. Keep reading to learn how to protect vision.
Nikkhil K Masurkar Wednesday, January 14, 2026, 08:00 Hrs [IST] Myopia is a widespread vision issue affecting over two ...
As of Friday, January 09, Coherus Oncology, Inc.’s CHRS share price has surged by 6.86%, which has investors questioning if ...
Full-year 2025 preliminary1 U.S. net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) total injection demand grew 17% ...
Samsung Bioepis announced that the company has begun direct commercialization of BYOOVIZ®, a biosimilar to Lucentis (ranibizumab), in Europe.
Clerio Vision, Inc., a developer of next-generation laser-based vision correction platforms, today announced the issuance of U.S. Patent No. 12,443,053 B2, titled "Myopia Control Treatments". The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback